



23 August 2021

Health House International signs exclusive import and distribution agreement with Smartway Pharmaceuticals

- **Exclusive Importation and Distribution Agreement signed with Smartway Pharmaceuticals Limited.**
- **Agreement expands Health House’s product portfolio within the United Kingdom.**
- **Smartway to import and supply cannabis-based products for medicinal use (CBPMs) leveraging its regulatory authorisations and Health House’s Cannabis Supply network.**
- **Health House to Distribute CBPM’s initially throughout the UK**

Health House International Limited (**ASX:HHI**) (**Health House** or **the Company**) is pleased to announce it has signed an exclusive importation and distribution agreement (**Agreement**) with **Smartway Pharmaceuticals Limited (Smartway)**.

The Agreement will see Smartway import and supply cannabis-based products using its extensive regulatory knowledge and authorisations, and utilising Health House’s cannabis supply network. The agreement will see Health House and Smartway import CBPMs (which are manufactured in accordance with Good Manufacturing Practice) into the UK for medicinal use. Health House and Smartway will distribute CBPMs via their extensive networks, initially throughout the UK.

Health House Chief Executive Officer, David Attwood said “This agreement between Health House and Smartway will combine the strengths of each party in ensuring that healthcare professionals in the UK and ultimately, their patients have a broad access to the very best cannabis-based medicines from all over the world”

Josh Cocklin, Chief Executive at Smartway Pharmaceuticals, adds: “Smartway is a global leader in designing and delivering ethical and compliant access programs for products not yet licenced in a country. Smartway will leverage its regulatory knowledge and authorisations to enable efficient, safe and complaint distribution of these products. Smartway has a global supply network spanning over 100 countries and supplies directly to over 1,000 UK pharmacies.”

DISCLOSURES:

- The commencement date of the Agreement is 22 August 2021
- The Company cannot, at this stage, fully quantify the impact of the contract will have on the price of its securities.
- The Agreement shall continue unless terminated by either party giving 6 months written notice.

This announcement has been approved and authorised for release by the board of Health House International Limited.

David Wheeler
Chairman

About Health House (www.healthhouse.com.au)

Health House International is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Company is a fully licenced and regulated specialised importer, exporter, consolidator and distributor of medicinal currently distributing 14+ medicinal cannabis products to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. With its Wholesale Dealers and Controlled Drugs licences the Company supplies pharmacies, hospital, government departments, veterinarians and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe.

Address

Level 3, 101 St Georges Tce
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: admin@healthhouse.com.au
W: www.healthhouse.com.au
ACN 149 197 651

Contact:

David Attwood
David.attwood@healthhouse.com.au

Tim Slate
tim@catalystcorporate.com.au

About Smartway Pharmaceuticals (www.smartwaypharma.com):

Smartway is a global pharmaceutical specialist distributor focussed on 'Transforming Patients lives by empower access to medicines globally'. It is headquartered in the UK with fully owned and controlled network companies across the EU, and rest of the world.

Smartway founded in 1992, distributes to well over 100 countries. It partners with global pharma and biotech companies to design, implement and manage Expanded Access Programs and compliant distribution solutions to empower access to medicines for patients with unmet clinical needs.

Address

10 Lyon Road

London SW19 2RL

United Kingdom

Tel: +44 (0)20 8545 7711

E: helpme@smartwaypharma.com

W: www.smartwaypharma.com

Contact:

Dhruv Patel

Tel: +44 (0)20 8545 7711

E: dhruv.patel@smartwaypharma.co.uk

Media Relations

Anna Vassova

Tel: +44 (0)20 8545 7711

E: anna.vassova@smartwaypharma.co.uk